Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial

BMC Nephrology

Deborah L Zimmerman⁴  Janet L Davis²  Ayub Akbari⁴  Adam Cohn³  Shankar P Nagaraju¹ 

[1]Department of Nephrology, Kasturba Medical College, Manipal, Karnataka, India

[2]Department of Medicine, Division of Nephrology, Ottawa, ON, Canada

[3]Department of Medicine, Queensway Carleton Hospital, Ottawa, ON, Canada

[4]Department of Medicine, Division of Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada

关键词: Chronic kidney disease;    Iron;    Anemia;   

Others  :  1082975
DOI  :  10.1186/1471-2369-14-64

 received in 2012-09-27, accepted in 2013-03-13,  发布年份 2013

【 摘 要 】

Background

Anemia secondary to iron deficiency is common in patients with non-dialysis dependent chronic kidney disease (ND-CKD) but it is unclear if oral supplementation is as effective as intravenous (IV) supplementation in re-establishing iron stores. The purpose of this study was to determine if oral Heme Iron Polypeptide (HIP) is as effective as IV iron sucrose in the treatment of iron-deficiency anemia for patients with ND-CKD.

Methods

Forty ND-CKD patients were randomized; 18 to HIP 11 mg orally 3 times per day and 22 to IV iron sucrose 200 mg monthly for 6 months. Baseline clinical and laboratory data were collected for all patients. The primary and secondary outcomes for the study were hemoglobin (Hgb) concentration and iron indices [ferritin and percentage transferrin saturation (TSAT)] at the end of 6 months respectively. Adverse events were also compared.

Results

The baseline demographic characteristics and laboratory values were similar for the two groups. After 6 months of treatment, Hb in the HIP group was 117 g/L and 113 g/L in the IV sucrose group (p = 0.37). The TSAT at 6 months was not different between the two groups {p = 0.82}but the serum ferritin was significantly higher in the IV iron sucrose group {85.5 ug/L in HIP and 244 ug/L; p = 0.004}. Overall adverse events were not different between the groups.

Conclusion

HIP is similar in efficacy to IV iron sucrose in maintaining hemoglobin in ND-CKD patients with no differences in adverse events over 6 months. It is unclear if the greater ferritin values in the IV iron sucrose group are clinically significant.

Trial registration

ClinicalTrials.gov: NCT00318812

【 授权许可】

   
2013 Nagaraju et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Regidor DL, Kopple JD, Kovesdy CP, Kilpatrick RD, McAllister CJ, Aronovitz J, Greenland S, Kalantar-Zadeh K: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006, 17:1181-91.
• [2]Hsu CY, McCulloch CE, Curhan GC: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third National Health and Nutrition examination survey. J Am Soc Nephrol 2002, 13:504-10.
• [3]Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999, 34:125-34.
• [4]Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987, 316:73-78.
• [5]Macdougall IC, Hutton RD, Cavill I, Coles GA, Williams JD: Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ 1989, 299:157-58.
• [6]Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996, 27:234-8.
• [7]Danielson B: R-HuEPO hyporesponsiveness—who and why? Nephrol Dial Transplant 1995, 10(suppl 2):S69-S73.
• [8]Hsu CY, McCulloch CE, Curhan GC: Iron status and hemoglobin level in chronic renal insufficiency. J Am Soc Nephrol 2002, 13:2783-6.
• [9]Gotloib L, Silverberg D, Fudin R, Shostak A: Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol 2006, 19:161-7.
• [10]Beard JL: Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutrition 2001, 131:568S-580S.
• [11]Fishbane S: Iron supplementation in renal anemia. Semin Nephrol 2006, 26:319-324.
• [12]Horl WH: Clinical aspects of iron use in the anemia of kidney disease. JAm Soc Nephrol 2007, 18:382-93.
• [13]VanWyck DB, Cavallo G, Spinowitz BS, Adhikarla R, Gagnon S, Charytan C, Levin N: Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial. Am J Kidney Dis 2000, 36:88-97.
• [14]Walters BA, Van Wyck DB: Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients. Nephrol Dial Transplant 2005, 20:1438-42.
• [15]Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004, 65:2279-89.
• [16]Zager RA, Johnson AC, Hanson SY: Parenteral iron therapy exacerbates experimental sepsis. Kidney Int 2004, 65:2108-12.
• [17]Brewster UC, Perazella MA: Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004, 17:57-60.
• [18]Zager RA, Johnson AC, Hanson SY, Wasse H: Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002, 40:90-103.
• [19]Macdougall IC: Strategies for iron supplementation: oral versus intravenous. Kidney Int 1999, 55(Suppl 69):S61-6.
• [20]Nyvad O, Danielsen H, Madsen S: Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients [letter]. Lancet 1994, 344:1305-6.
• [21]Silverberg DS, Blum M, Peer G, Kaplan E, Iaina A: Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron 1996, 72:413-7.
• [22]Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Bulleton BF, Tonelli M, Manns BJ: Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int 2008, 74(suppl 110):S7-11.
• [23]Barraclough KA, Noble E, Leary D, Brown F, Hawley CM, Campbell SB, Isbel NM, Mudge DW, van Eps CL, Sturtevant JM, Johnson DW: Rationale and design of the oral HEMe iron polypeptide against treatment with oral controlled release iron tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). BMC Nephrology 2009, 10:20. BioMed Central Full Text
• [24]Stoves J, Inglis H, Newstead CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001, 16:967-74.
• [25]Charytan C, Quinibi W, Bailie GR: Comparison of intravenous iron sucrose to oral iron in the treatment of anemic patients with chronic kidney disease not on dialysis. Nephron Clin Pract 2005, 100:c55-c62.
• [26]Aggarwal HK, Nand N, Singh S, Singh M, Hemant Kaushik G: Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. JAssoc Physicians India 2003, 51:170-4.
• [27]Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S: A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int 2005, 68:2846-56.
• [28]Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ: Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008, 19:1599-605.
• [29]Grasbeck R, Kouvonen I, Lundberg M, Tenhunen R: An intestinal receptor for heme. Scand J Haematol 1979, 23:5-9.
• [30]Uzel C, Conrad ME: Absorption of heme iron. Semin Hematol 1998, 35:27-34.
• [31]Seligman PA, Moore GM, Schleicher RB: Clinical studies of HIP: an oral heme-iron product. Nutr Res 2000, 20:1279-86.
• [32]Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD: Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med 2000, 135(6):452-8.
• [33]Hallberg L, Hulten L, Gramatkovski E: Iron absorption from the whole diet in men: how effective is the regulation of iron absorption? Am J Clin Nutr 1997, 66:347-56.
• [34]Nissenson AR, Berns JS, Sakiewicz P, Ghaddar S, Moore GM, Schleicher RB, Seligman PA: Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients. Am J Kidney Dis 2003, 42:325-30.
• [35]Agarwal R, Rizkala AR, Bastani B, Kaskas MO, Leehey DJ, Besarab A: A randomized controlled trial of oral versus intravenous iron in chronic kidney disease. Am J Nephrol 2006, 26:445-54.
• [36]Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD: A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011, 26:1599-607.
• [37]Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U: Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008, 52:897-906.
• [38]Barrraclough KA, Brown F, Hawley CM, Leary D, Noble E, Campbell SB, Isbel NM, Mudge DW, van Eps CL, John DW: A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anemia in peritoneal dialysis patients: HEMOATOCRIT trial. Nephrol Dial Transplant 2012, 27:4146-4153.
• [39]A clinical trial of oral versus IV iron in patients with chronic kidney disease. http://www.clinicaltrials.gov webcite, clinical trial NCT00830037